Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?

Simple item page
dc.contributor.authorJorge Soliz
dc.contributor.authorEdith M. Schneider Gasser
dc.contributor.authorChristian Arias‐Reyes
dc.contributor.authorFernanda Aliaga‐Raduán
dc.contributor.authorLiliana Poma-Machicao
dc.contributor.authorGustavo Zubieta‐Calleja
dc.contributor.authorWerner I. Furuya
dc.contributor.authorPedro Trevizan‐Baú
dc.contributor.authorRishi R. Dhingra
dc.contributor.authorMathias Dutschmann
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:02:23Z
dc.date.available2026-03-22T21:02:23Z
dc.date.issued2020
dc.descriptionCitaciones: 88
dc.identifier.doi10.1016/j.resp.2020.103476
dc.identifier.urihttps://doi.org/10.1016/j.resp.2020.103476
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/85568
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofRespiratory Physiology & Neurobiology
dc.sourceUniversité Laval
dc.subjectMedicine
dc.subjectErythropoietin
dc.subjectHypoxemia
dc.subjectIntensive care medicine
dc.subjectHypoxia (environmental)
dc.subjectRespiratory system
dc.subjectContext (archaeology)
dc.subjectRhinovirus
dc.subjectImmunology
dc.subjectInternal medicine
dc.titleCoping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
dc.typereview

Files

Collections

Artículo Científico Publicado